Identification of aberrant tRNA-halves expression patterns in clear cell renal cell carcinoma

Malin Nientiedt1, Mario Deng2,3, Doris Schmidt1, Sven Perner2,3, Stefan C. Müller4 & Jörg Ellinger1

Small non-coding RNAs (sncRNA; < 200 nt) regulate various cellular processes and modify gene expression. Under nutritional, biological or physiochemical stress some mature sncRNAs (e.g. tRNAs) are cleaved into halves (30–50 nt) and smaller fragments (18–22 nt); the significance and functional role of these tRNA fragments is unknown, but their existence has been linked to carcinogenesis. We used small RNA sequencing to determine the expression of sncRNAs. Subsequently the findings were validated for miR-122-5p, miR-142-3p and 5’tRNA4-Val-AAC using qPCR. We identified differential expression of 132 miRNAs (upregulated: 61, downregulated: 71) and 32 tRNAs (upregulated: 13, downregulated: 19). Read length analysis showed that miRNAs mapped in the 20–24 nt fraction, whereas tRNA reads mapped in the 30–36 nt fraction instead the expected size of 73–95 nt thereby indicating cleavage of tRNAs. Overexpression of miR-122-5p and miR-142-3p as well as downregulation of 5’tRNA4-Val-AAC was validated in an independent cohort of 118 ccRCC and 74 normal renal tissues. Furthermore, staging and grading was inversely correlated with the 5’tRNA4-Val-AAC expression. Serum levels of miR-122-5p, miR-142-3p and 5’tRNA4-Val-AAC did not differ in ccRCC and control subjects. In conclusion, 5’ cleavage of tRNAs occurs in ccRCC, but the exact functional implication of tRNA-halve deregulation remains to be clarified.

Renal cell carcinoma (RCC) is the most frequent renal malignancy accounting for 80–85% of the primary renal tumors. The incidence of RCC is still increasing, especially the number of young patients and high-grade disease is rising1. The increasing number of small renal tumors may be explained by the widespread use of abdominal ultrasonography for check-up or clarification of non-specific symptoms. A substantial number of these small renal tumors turns out to be benign. Current imaging modalities do not allow precise identification of malignant tumors2, percutaneous biopsy has several limitations impeding the acceptance of the method3, and thus overtherapy is common as many renal masses are benign4. Thus, additional diagnostic parameters could help the clinician to improve patients treatment. Furthermore, small tumors are often growing slowly and active surveillance are alternative treatment options getting an increased acceptance in selected patients5. But, early identification of aggressive tumors is desirable as prognosis of advanced/metastatic RCC is poor: surgery (cytoreductive nephrectomy, metastasectomy) and targeted therapy improved patient’s survival, but eventually most patients decease as a consequence to the disease6.

Up until now, no biomarker is available for clinical practice, making an accurate and non-invasive identification of RCC impossible. Non-coding RNAs, especially small non-coding RNAs (sncRNA; < 200 nt), have attracted the attention of biomarker researchers as sncRNAs act as a regulator of various cellular processes and may have oncogenic or tumor suppressive properties. miRNA, as a subclass of sncRNA, expression profiles have been established in RCCs7, and the detection of miRNAs in bodily fluids allows their use as non-invasive biomarker for patients with urological malignancies8. In contrast to miRNAs, few is known about the expression of the other sncRNA types, such as tRNA, sn(o)RNA and piRNA9. To improve the understanding of such interactions, we determined the expression profile of sncRNAs in clear cell renal cell carcinoma (ccRCC). We observed altered expression of truncated tRNA fragments in ccRCC. Among several deregulated tRNA, we identified 5’tRNA4-Val-AAC as downregulated in ccRCC, and furthermore its expression was correlated with advanced stage and grade.

1University Hospital Bonn, Department of Urology, Bonn, Germany. 2Pathology of the University Medical Center Schleswig-Holstein, Campus Luebeck, Luebeck, Germany. 3Research Center Borstel, Leibniz Center for Medicine and Biosciences, Borstel, Germany. Correspondence and requests for materials should be addressed to J.E. (email: joerg.ellinger@ukb.uni-bonn.de)
## Results

### Small RNA expression profiling.

Small RNA expression including miRNAs, tRNAs, piRNAs and sn(o)RNAs was profiled using small RNA sequencing. We investigated the sncRNA profile in a discovery cohort of 18 corresponding ccRCC and normal renal tissue samples. We observed differential expression (defined as log2-fold expression difference > 2 and p-value < 0.05) of 132 miRNAs: 61 miRNAs were upregulated and 71 were downregulated in ccRCC. Many of these differentially expressed miRNAs have been reported before, but we also identified deregulated miRNAs not yet known to have a potential impact on ccRCC pathogenesis (e.g. miR-142-3p, miR-885-5p, miR-1910-5p, miR-186-3p, miR-4652-5p, miR-6737-3p, miR-508-5p, miR-513c-5p, miR-4485-3p, miR-513a-5p, miR-4461). A summary of the 10 most up- and downregulated miRNAs in ccRCC is provided in Table 1. As expected, miRNA expression profiles allowed precise discrimination of normal and ccRCC tissues: a multi-dimensional scaling plot identifies two clearly separable clusters of ccRCC and normal renal tissue samples, as shown in Fig. 1A. The volcano plot in Fig. 1B demonstrates the miRNA expression differences in normal and ccRCC tissue. A heatmap of miRNA expression in renal tissues is provided in Supplementary Figure S1.

Beside the enrichment of miRNA, read length distribution analysis showed a second peak of RNA in the 30–36 nt part. Annotation analysis revealed that these reads derived from tRNAs (see Fig. 2). Among the 345 analyzed tRNA transcripts, we found 32 differentially expressed tRNAs: among these, 13 tRNA were upregulated and 19 were downregulated in ccRCC. A summary of the 10 most up- and downregulated tRNAs in ccRCC is listed in Table 2. The differential tRNA expression is shown in a volcano plot in Fig. 1C. A heatmap of tRNA expression in renal tissues is provided in Supplementary Figure S2.

For a better understanding, gene wise expression and cluster analyses have been done using log2 normalized pseudo counts. Supplementary Figure S3 provides an overview about the homogeneity of gene expression of three selected targets. Comparable plots were observed for all significantly expressed miRNA or tRNA.

piRNAs were found in both tissue types, but only few of the sample reads did reach the small RNA sequencing normalization cutoff of 4 reads. Thus, most of them have not fulfilled the coverage of at least 1 counts per million (CPM) in each of two paired samples. Consequently, further analysis for these sncRNAs could not be performed. sn(o)RNA and rRNA-fragments were not found to be differentially expressed at all.

### Validation of small non-coding RNA expression.

In order to confirm differential expression of selected sncRNAs we performed quantitative real-time PCR (qRT-PCR). The expression levels of 5’tRNA4-Val-AAC (small RNA sequencing: fold-change - 6.648, p-value 0.0009, logCPM 19.473), miR-122-5p (small RNA sequencing: fold-change 8.148, p-value < 0.001, logCPM 5.101) and miR-142-3p (small RNA sequencing: fold-change 2.182, p-value < 0.001, logCPM 8.220) were studied in a validation cohort of ccRCC (n = 118) and normal (n = 74) renal tissue samples. As expected from the small RNA sequencing experiments, we noticed significant upregulation of miRNA-122-5p and miRNA-142-3p in ccRCC samples (p < 0.001). In contrast, miR-122-5p expression levels were decreased in metastatic ccRCC (p = 0.006). The expression levels of both miRNAs were not correlated with other clinicopathological parameters (pT-stage, lymph node metastasis, grade, age, sex; all p > 0.05).

| miRNA            | log2-FC | p-value | logCPM |
|------------------|---------|---------|--------|
| miR-122-5p       | 8.148   | 1.70E-36| 5.101  |
| miR-885-5p       | 3.500   | 3.33E-10| 3.266  |
| miR-1910-5p      | 4.995   | 5.06E-08| 1.037  |
| miR-592          | 4.703   | 2.26E-23| 5.474  |
| miR-3174         | 4.690   | 3.29E-07| -0.030 |
| miR-186-3p       | 4.465   | 0.0003  | -0.140 |
| miR-4705         | 4.356   | 0.0010  | -0.148 |
| miR-4652-5p      | 4.299   | 0.0011  | -0.174 |
| miR-6737-3p      | 4.277   | 0.0004  | -0.213 |
| miR-885-3p       | 4.188   | 0.0212  | -0.196 |

Table 1. Differential expression of miRNAs in ccRCC and normal renal tissue. The logCPM value presents the mean log-average concentration/abundance of the 18 corresponding samples for each tag in the two groups being compared.
As shown in Supplementary Figure S4, we also performed qRT-PCR to determine the expression level of the full-length tRNA4-Val-AAC transcript in each 10 normal and ccRCC renal tissues. Interestingly, we did not notice any expression difference of the expression level between the normal and ccRCC tissue ($p = 0.905$).

In contrast to this, we confirmed a significant decrease of 5′tRNA4-Val-AAC halves in ccRCC ($p < 0.001$). Also 5′tRNA4-Val-AAC levels were negatively correlated with tumor stage and grade: the decrease of 5′tRNA4-Val-AAC was more distinct in advanced (UICC stage III/IV vs. stage I/II: $p = 0.001$) and less differentiated (grade 1/2 vs. grade 3/4: $p = 0.002$) ccRCC. A boxplot figure indicating the expression differences is shown in Figs 3 and 4.

**Analysis of serum miR-142-3p, miR-122-5p and 5′tRNA4-Val-AAC levels.** We also studied the expression of sncRNAs in serum samples obtained before nephrectomy to investigate the potential as non-invasive biomarker. However, we did not notice differential expression of miR-142-3p, miR-122-5p and 5′tRNA4-Val-AAC in serum samples ($p > 0.05$) in a cohort of 30 ccRCC patients and 15 healthy individuals. See Fig. 5.

**Functional analysis of miRNA-mRNA target interactions and relationships.** We next used Cancerminer to evaluate functional miRNA-mRNA target interactions and relationships. Interaction of miR-122 and mRNAs was predicted for CDCA7L (cell division cycle associated 7-like), CREG2 (cellular repressor of...
E1A-stimulated genes 2), IGLON5 (IgLON family member 5), FAM153C (family with sequence similarity 153, member C), LRRC10B (leucine rich repeat containing 10B), C3orf70 (chromosome 3 open reading frame 70), ARHGEF39 (Rho guanine nucleotide exchange factor (GEF) 39) and GRM5 (glutamate receptor, metabotropic 5. Notably, miRNA-122 is only expressed in glioblastoma multiforme and ovarian serous cystadenocarcinoma (REC-score between 2.13–3.16) besides of ccRCC within the TCGA dataset. Contrary to this miRNA-142 has a widespread expression in cancer tissue (REC-score between 2.09–16.93). It is known to be expressed in glioblastoma multiforme, ovarian serous cystadenocarcinoma, colon and rectal adenocarcinoma, lung squamous cell carcinoma, breast invasive carcinoma, uterine corpus endometrioid carcinoma, head and neck squamous cell carcinoma and lung adenocarcinoma. We identified 91 positive and significant mRNA target interactions. To mention the most important ones: CD2 molecule, ZNF831 (zinc finger protein 831), IKZF1 (IKAROS family zinc finger protein 1), GFI1 (growth factor independent 1 transcription repressor) and the XCL1 (chemokine ligand 1).

### Table 2. Differential expression of tRNAs in ccRCC and normal renal tissue.

| tRNA       | log2 FC | p-value  | logCPM |
|------------|---------|----------|--------|
| tRNA38_LeuCAG  | 5.251   | 0.0021   | 9.566  |
| tRNA12_ProAGG  | 4.532   | 0.0096   | 8.494  |
| tRNA8_ThrAGT    | 4.440   | 0.0068   | 7.399  |
| tRNA86_ArgTCT   | 4.421   | 0.0161   | 7.387  |
| tRNA164_MetCAT  | 4.274   | 0.0021   | 7.336  |
| tRNA84_GluTTC   | 4.206   | 0.0184   | 7.304  |
| tRNA87_GluCTC   | 3.869   | 0.0418   | 16.177 |
| tRNA2_LysTTT    | 3.644   | 0.0337   | 11.914 |
| tRNA98_LeuAAG   | 3.517   | 0.0282   | 8.058  |
| tRNA2_ProAGG    | 3.506   | 0.0291   | 7.452  |

### Downregulated in ccRCC:

| tRNA       | log2 FC | p-value  | logCPM |
|------------|---------|----------|--------|
| tRNA9_ValCAC | −6.736  | 0.0037   | 17.899 |
| tRNA18_ArgCCT | −6.684  | 0.0027   | 13.285 |
| tRNA4_ValAAC  | −6.648  | 0.0009   | 19.473 |
| tRNA5_GluTTC  | −5.560  | 0.0120   | 13.972 |
| tRNA43_SerGCT | −5.125  | 0.0284   | 8.029  |
| tRNA22_ProAGG | −4.875  | 0.0074   | 11.832 |
| tRNA136_ValAAC | −4.864  | 0.0185   | 18.086 |
| tRNA2_LeuTAA  | −4.752  | 0.0120   | 8.086  |
| tRNA6_ValCAC  | −4.678  | 0.0185   | 15.873 |
| tRNA128_GlyGCC | −4.655  | 0.0245   | 16.871 |

### Figure 3. Validation of sncRNA expression using quantitative real-time PCR.

The expression levels of 5′ tRNA4-Val-AAC, miR-122-5p and miR-142-3p were different in ccRCC (n = 118) compared to normal (n = 74) renal tissue.
Discussion

Despite of the numerous efforts to identify biomarkers for patients with RCC, there are currently none biomarkers available for daily practice. sncRNAs, especially miRNAs, have been suggested as novel diagnostic/prognostic biomarkers. In order to increase the understanding and function on other sncRNA subtypes, we applied small RNA sequencing to sncRNAs and identified novel potential biomarkers for ccRCC.

The most interesting finding of our study is the identification of a large number (32 transcripts) of differentially expressed tRNA-halves, which has not been described before. We exemplarily validated downregulation of 5′tRNA4-Val-AAC in ccRCC using quantitative real-time PCR in an independent cohort of 118 ccRCC and 74 normal renal tissues. The potential relevance of this tRNA-halve is highlighted by the finding of the decreased 5′tRNA4-Val-AAC levels in patients with advanced stages and less differentiated ccRCC. Müller et al.12 evaluated a small RNA sequencing dataset (GSE24457) containing 10 ccRCC and normal samples, and thereby identified two downregulated tRNA derived fragments (tRNA-Leu-TTA and tRNA-Ser-TCA) in ccRCC12.

It was recognized that tRNA-halves circulate in a stable form in the bloodstream as particles of 100–300 kDa, but not in exosomes or other microvesicles. tRNA-halves were subjected to regulation by age and calorie restriction. Notably, various tRNA fragments in serum were circulating at different levels in breast cancer14 and head and neck squamous cell carcinoma15 patients compared to control subjects, suggesting a role as non-invasive cancer biomarker. We thus also investigated the levels of 5′tRNA4-Val-AAC in serum of ccRCC patients, but did not notice differential expression in a small cohort of ccRCC patients and healthy controls.

The read length analysis indicated that the differentially expressed tRNAs were truncated to 30 to 35 nt fragments, whereas mature tRNAs are 73 to 95 nt sized. For a long time, tRNAs were solely known for their role in translation to decode nucleotide triplets for the protein synthesis. However, under nutritional, biological or physiochemical stress, but also under physiological conditions, mature tRNAs are cleaved into 5′halves (30–35 nt) and 3′halves (40–50 nt), as well into 5′tRFs and 3′tRFs (18–22 nt). In eukaryotes, the RNase Angiogenin produces tRNA-halves through specific cleavage near or in the anticodon loop. There is an increasing evidence that tRNA-halves have a functional role: 5′tRNA-halves inhibit translation for preservation of cellular energy under stress conditions, protect cells from apoptosis by sequestering cytochrome c and induce angiogenesis. They influence the formation of stress granules, which are targeting the translation initiation complex.
involvement in key biological processes strongly suggests a functional role of tRNA-halves in RCC carcinogenesis. Their well-directed cleavage let us suggest that renal cancer cells are able to control the various tRNA-halves amounts quantitatively and qualitatively, which permits them a good and resistant stress adaptation. It was already demonstrated that sex hormone-dependent tRNA-halves enhance cell proliferation in breast and prostate cancer.\(^2\)

miRNA expression has widely been studied in the past: tumor-specific miRNA expression profiles have been identified\(^3\), and miRNA profiles allow even specific identification of RCC subtypes.\(^4\) The identification of circulating miRNAs in patients blood\(^24\) and their tremendous functional impact on carcinogenesis encouraged many researchers to study this RNA entity in ccRCC. In agreement with previous studies\(^2\)\(, 7\)\(, 12\)\(, 27\)\(−\)\(30\), we were able to classify ccRCC and normal renal tissue based on the miRNome: we were able to detect 770 miRNA transcripts, and 17.1% (n = 132) were differentially expressed in ccRCC. In order to exemplarily validate the sequencing data, we determined the expression of miR-122-5p and miR-142-3p in an independent cohort of 118 ccRCC and 70 normal renal tissues. As expected, dysregulation of both miRNAs in ccRCC tissue was confirmed. An oncogenic function seems reasonable as miR-142-3p increased cancer cell proliferation through TGFβRII repression in non-small cell lung cancer cell lines\(^31\) and activation of the WNT signaling pathway in breast cancer cells\(^32\). miR-122-5p was upregulated in primary renal tumors, but was observed downregulated during the metastatic process, a special finding also described by Wotschofsky \(et al.\)\(^{12}\) miR-122 acted in ccRCC cells as oncomir through activation of the PI3K/Akt signal pathway\(^33\) and was identified to target the VHL-HIF-hypoxia pathway\(^34\). Notably, circulating miR-122 facilitated metastasis by increasing nutrient availability in the premetastatic niche of breast cancer by inhibition of glucose uptake in normal cells\(^35\).

The class of piRNAs (26–32 nt) were identified 2006 in germline cells as a regulator of genomic stability; they take part in important cellular functions like transposon silencing, epigenetic regulation, proliferation and apoptosis. They have also been detected in various human somatic tissues\(^36\). Furthermore, it was shown that specific piRNA expression patterns in cancer cells exist\(^37\). However, our study does not support a role of piRNAs in ccRCC carcinogenesis.

Further on, several circulating miRNAs have been identified for some urological malignancies, like prostate cancer\(^38\), bladder cancer\(^39\) and RCC.\(^26\) As miRNA tissue and serum expression profiles are often different, we investigated the expression of miR-122-5p, miR-142-3p and 5’tRNA4-A4-Val-AAC-halve in an independent cohort of 45 serum samples. We observed that miRNAs as well as 5’tRNA-halves exist as circulating nucleic acids, but the expression levels did not differ in the ccRCC and the control cohort. This finding raises issues concerning the sncRNAs origin, their processing, their destination, their secretion mechanism, their transport and their target location. It seems possible that 5’tRNA-halves circulate in the bloodstream as part of a larger complex\(^13\) and miRNAs are suspected to be released passively and uncombined during tissue injury into serum or to be actively secreted in the circulation as microvesicles\(^40\). Therefore it is to determine whether do ccRCC change itself the sncRNA expression level and which extracellular functions do sncRNAs fulfill. Further, it remains unclear why the serum sncRNA expression profile differs from the sncRNA tissue profile. We expect that further studies can help to elucidate the sncRNA expression of ccRCC in bodily fluids and can shed light to the elusive molecular mechanism of sncRNA.

Some limitations of our study should also be acknowledged: we did not include technical replicates in our small RNA sequencing experiments, and thus data may have been misinterpreted. However, we ensured reliability by analyzing a large number of biological replicates (i.e. each 18 ccRCC and normal samples) in the sequencing experiment, and validation the finding of altered tRNA/miRNA expression in an independent, large-scale validation cohort (118 ccRCC and 74 normal) using a different detection technique (PCR). It should also be noted that only 3 biomarkers were validated using PCR, although the expression of 132 miRNAs and 32 tRNAs was shown to be altered in ccRCC tissue. The expression differences in localized/advanced respectively low/high grade ccRCC seem to be small, although we observed a statistical significance; validation in an independent cohort is warranted. Functional analysis by computational methods enabled us to get an idea of the role of miR-122-5p and miR-142-3p in ccRCC development. Cancerminer use the huge molecular dataset from ‘The Cancer Genome Atlas’, so its results exhibit great empirical evidence. Nevertheless we should keep in mind, that bioinformatic data sources follow always a committed algorithm, which cannot cover all aspects of gene regulation and interactions.

**Methods**

**Patients.** Fresh frozen tissues from patients undergoing radical or partial nephrectomy were prospectively collected according standard operating procedures in the Biobank at the CIO Cologne-Bonn at the University Hospital Bonn. Samples were stored at −80 °C until usage. Renal tissue samples were collected between 1996 and 2014 from patients undergoing partial or radical nephrectomy for RCC; the samples were chosen randomly from the Biobank. All samples were reviewed using haematoxylin and eosin-stained sections by an experienced uropathologist (S.P.). RCC staging was performed according the 7th edition of the TNM classification from 2009.

We also collected prospectively serum from ccRCC patients undergoing radical nephrectomy or partial nephrectomy as well as patients with non-malignant urological diseases between 2005 and 2011 at the Departments of Urology at the Universitätsklinikum Bonn (UKB). Blood was withdrawn preoperatively in Serum S-Monovette Gel tubes with clotting activator (Sarstedt, Nümbrecht, Germany). After clotting and centrifugation serum was separated and stored in cryotubes at −80 °C. The samples were processed within 3 hours.

All patients provided written informed consent and the study was approved by the Ethikkommission at the Universitätsklinikum Bonn (number: 280/12). All experiments were performed in accordance with relevant guidelines and regulations. The detailed clinical-pathological parameters of the study cohorts are reported in Table 3.
RNA isolation. Total RNA was isolated using the mirVana miRNA Isolation Kit (Ambion, Foster City, CA, USA) and was two times DNAse-treated (DNA-free Kit, Ambion) according to the manufacturer's recommendation. A detailed description was provided earlier41. RNA quality and quantity was measured (NanoDrop 2000 spectrophotometer, Thermo Scientific, Wilmington, DE, USA). RNA integrity of the samples was determined with a RNA 6000 Nano Kit on the Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA); only samples with a RIN \( > 6 \) were used for small RNA sequencing experiments. Furthermore, all samples were investigated using agarose gel electrophoresis to exclude RNA degradation. Serum RNA isolation was performed as published earlier using the mirVana Paris-Kit (Ambion) from 400 \( \mu l \) serum38.

Small RNA Sequencing. Small RNA sequencing was performed by Biogazelle (Zwijnaarde, Belgium) as a contract service. RNA isolates from 18 corresponding normal renal and ccRCC tissues (500 ng total RNA) were sent on dry ice to Biogazelle. Small RNA libraries were sequenced on an Illumina NextSeq500. Mapping was performed using the short-read aligner Bowtie (http://bowtie.cbcb.umd.edu). Bowtie is a free, open source software, which aligns ultrafast and memory-efficient Illumina reads to the human genome version 19. Mapped reads were subsequently annotated to different contaminants (tRNA, rRNA, sn(o)RNA, piRNA) and mature miRNA using Ensembl genome annotation database42, UCSC Genome browser43, miRBase v2044, and genomic tRNA database 200945. Mismatches were not allowed. In case of multi-mapped reads, we assigned the reads to the sncRNA with the lowest offset. Supplementary Figure S5 demonstrates mean variance plots and scatterplots of miRNA and tRNA expression levels, used to ensure internal quality assurance.

Statistical analysis has been performed using the R programming language and the edgeR46 package following workflow proposed by Anders et al.47. Therefore, Counts Per Millions (CPM) have been calculated and sncRNA having less than 1 CPM in each sample pair been removed. This reduced the number of miRNAs from 2576 to 770 and of tRNAs from 624 to 345. For further analysis read counts have been normalized to the corresponding library sizes using edgeR’s calcNormFactors function and sample variation has been taken into account by calculation the dispersion coefficients using the estimateCommonDisp, estimateTagwiseDisp functions. Detection of differentially expressed sncRNA has been performed using the exact test, as suggested by Robinson and Smyth and implemented edgeR’s exactTest function48. Subsequently, a sncRNA has been called differentially expressed if its fold change was \( > 2 \) or \( < (-2) \) and its p-value \( < 0.05 \) (after Benjamini-Hochberg correction). To validate these finding a Generalized Linear Model (GLM) has been fitted to the data and detection of differentially expressed sncRNA has been done using the Likelihood Ratio Test (LRT), implemented as glmFit and glmLRT in the edgeR package, with both methods yielding identical results. Cluster and miRNA/tRNA wise expression analyses has been done using log2 normalized pseudo counts under consideration of the differentially expressed sncRNA from upstream operations. The raw data from small RNA sequencing experiments data are deposited at Gene Expression Omnibus (GEO) database (record: GSE73342).

Real-Time PCR. To validate the expression profiling experiments, we determined the expression of three differentially regulated targets. PCR experiments were performed on an ABI Prism 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). qRT-PCR experiments were performed with an independent cohort of 118 ccRCC and 74 normal renal tissue samples. In addition, a serum cohort (30 ccRCC and 15 healthy individuals) was investigated to determine the value of sncRNA as non-invasive biomarker. Therefore, cDNA was

|                | screening | ccRCC | CTRL | serum cohort | ccRCC | CTRL |
|----------------|-----------|-------|------|--------------|-------|------|
| Sex            |           |       |      |              |       |      |
| male           | 13 (82.2) | 81 (68.6) | 52 (70.3) | 18 (60.0) | 7 (46.7) |      |
| female         | 5 (27.8)  | 73 (31.4) | 22 (29.7) | 12 (40.0) | 8 (53.3) |      |
| Age            |           |       |      |              |       |      |
| mean           | 62.3      | 65.5  | 63.3 | 63.2         | 59.9  |      |
| min-max        | 43–81     | 36–89 | 35–89 | 42–82        | 41–79 |      |
| Pathological stage |     |       |      |              |       |      |
| pT1            | 9 (50.0)  | 68 (57.6) | n.a. | 15 (50.0)    | n.a.  |      |
| pT2            | 1 (5.6)   | 10 (8.5)  | n.a. | 0 (0)        | n.a.  |      |
| pT3            | 7 (38.9)  | 37 (31.4) | n.a. | 15 (50.0)    | n.a.  |      |
| pT4            | 1 (5.6)   | 3 (2.5)   | n.a. | 0 (0)        | n.a.  |      |
| lymph node metastasis | 0 (0) | 4 (3.4)  | n.a. | 1 (3.3)      | n.a.  |      |
| distant metastasis    | 1 (5.6)  | 17 (14.4) | n.a. | 1 (3.3)      | n.a.  |      |

Table 3. Clinicopathological parameters of the study cohorts. n.a., not applicable.
synthesized with 500 ng RNA using the miScript II RT Kit (Qiagen, Hilden, Germany). Quantitative real-time PCR (qRT-PCR) was performed with 5 ng/μl cDNA (tissue) or 6 μl (serum) cDNA template using Qiagen miScript SYBR Green PCR technology (Hilden, Germany). A pre-designed miScript Primer Assay was used to quantify the reference gene SNORD43 (HS000003416) and miR-142-3p (HS00031451); a custom made miScript Primer Assay (MDC0074992) was used to detect 5′tRNA4-Val-AAC. Data were analyzed using Qbase+ (Biogazelle) with SNORD43 as reference gene in the 2−ΔΔCT algorithm49; target genes were scaled to the control group. Statistical analyses (Mann-Whitney-U test) were performed with SPSS Statistics v21 (IBM, Ehningen, Germany).

References
1. Torre, L. A. et al. Global cancer statistics, 2012. CA: a cancer journal for clinicians 65, 87–108, doi: 10.3322/caac.21262 (2015).
2. Woo, S. & Cho, J. Y. Imaging findings of common benign renal tumors in the era of small renal masses: differential diagnosis from small renal cell carcinoma: current status and future perspectives. Korean journal of radiology 16, 99–113, doi: 10.3334/kjr.2015.16.199 (2015).
3. Blute, M. L., Jr., Drewry, A. & Abel, E. J. Percutaneous biopsy for risk stratification of renal masses. Therapeutic advances in urology 7, 265–274, doi: 10.1177/1756287215585273 (2015).
4. Johnson, D. C. et al. Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. The journal of urology 193, 39–45, doi: 10.1016/j.juro.2014.07.102 (2015).
5. Richard, P. O. et al. Active surveillance for renal neoplasms on oncotic features is safe. The journal of urology, doi: 10.1016/j.juro.2015.09.067 (2015).
6. Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: 2014 update. European urology 67, 913–924, doi: 10.1016/j.euro.2015.01.005 (2015).
7. Yousef, Y. M. et al. Accurate molecular classification of kidney cancer subtypes using microRNA signature. European urology 59, 722–739, doi: 10.1016/j.eururo.2011.01.004 (2011).
8. Ellinger, J. & Muller, S. C. MicroRNAs: a novel non-invasive biomarker for patients with urololgical malignancies. Current pharmaceutical biotechnology 15, 486–491 (2014).
9. Lee, S. K. & Calin, G. A. Non-coding RNAs and cancer: new paradigms in oncology. Discovery medicine 11, 245–254 (2011).
10. Jacobsen, A. et al. Analysis of microRNA-target interactions across diverse cancer types. Nat Struct Mol Biol 20, 1325–1332, doi: 10.1038/nsmb.2678 (2013).
11. Ellinger, J., Muller, S. C. & Dietrich, D. Epigenetic biomarkers in the blood of patients with urololgical malignancies. Expert review of molecular diagnostics 15, 505–516, doi: 10.1586/14737159.2015.1019477 (2015).
12. Muller, S. & Nowak, K. Exploring the miRNA-mRNA regulatory network in clear cell renal cell carcinomas by next-generation sequencing expression profiles. BioMed research international 2014, 948408, doi: 10.1155/2014/948408 (2014).
13. Dhahbi, J. M. et al. 5′tRNA halves are present as abundant complexes in serum, concentrated in blood cells, and modulated by aging and calorie restriction. BMC genomics 14, 298, doi: 10.1186/1471-2164-14-298 (2013).
14. Dhahbi, J. M., Spindler, S. R., Atamna, H., Boffelli, D. & Martin, D. I. Deep Sequencing of Serum Small RNAs Identifies Patterns of 5′tRNA Half and YRNA Fragment Expression Associated with Breast Cancer. Biomarkers in cancer 6, 37–47, doi: 10.4137/bic.s20764 (2016).
15. Victoria Martinez, B. et al. Circulating small non-coding RNA signature in head and neck squamous cell carcinoma. Oncotarget 6, 19246–19263 (2015).
16. Gebetsberger, J. & Polacek, N. Slicing tRNAs to boost functional ncRNA diversity. RNA biology 10, 1798–1806, doi: 10.4161/ rna.27177 (2013).
17. Anderson, P. S., Pivovarov, P. V. RNA fragments in human health and disease. FEBS letters 588, 4297–4304, doi: 10.1016/j.febslet.2014.09.001 (2014).
18. Yamasaki, S., Ivanov, P., Hu, G. F. & Anderson, P. Angiogenin cleaves tRNA and promotes stress-induced translational repression. The journal of cell biology 185, 35–42, doi: 10.1083/jcb.200811106 (2009).
19. Emara, M. M. et al. Angiogenin-induced tRNA-derived stress-induced RNAs promote stress-induced stress granule assembly. The journal of biological chemistry 285, 10959–10968, doi: 10.1074/jbc.M109.077560 (2010).
20. Saikia, M. et al. Angiogenin-cleaved tRNA halves interact with cytochrome c, protecting cells from apoptosis during osmotic stress. Molecular and cellular biology 34, 2430–2433, doi: 10.1128/mcb.00136-14 (2014).
21. Fu, H. et al. Stress induces tRNA cleavage by angiogenin in mammalian cells. FEBS letters 583, 437–442, doi: 10.1016/j.febslet.2008.12.043 (2009).
22. Honda, S. et al. Sex hormone-dependent tRNA half expression and cell proliferation in breast and prostate cancers. Proceedings of the National Academy of Sciences of the United States of America 112, E3816–E3825, doi: 10.1073/pnas.1510771112 (2015).
23. Volinia, S. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America 103, 2257–2261, doi: 10.1073/pnas.0510565103 (2006).
24. Wullken, L. M. et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PloS one 6, e25787, doi: 10.1371/journal.pone.0025787 (2011).
25. Hauser, S. et al. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer epidemiology 36, 391–394, doi: 10.1016/j.canep.2012.04.001 (2012).
26. Wang, C. et al. A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Scientific reports 5, 7610, doi: 10.1038/srep07610 (2015).
27. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43–49, doi: 10.1038/nature12223 (2013).
28. Weng, L. et al. MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen tissue and formalin-fixed, paraffin-embedded tissue specimens. The journal of pathology 222, 41–51, doi: 10.1002/path.2736 (2010).
29. White, N. M. et al. miRNA profiling for clear cell renal cell carcinoma: biomarker discovery and identification of potential controls and consequences of miRNA dysregulation. The journal of urology 186, 1077–1083, doi: 10.1016/j.juro.2011.04.110 (2011).
30. Osanto, S. et al. Genome-wide microRNA expression analysis of clear cell renal cell carcinoma by next generation deep sequencing. PloS one 7, e38298, doi: 10.1371/journal.pone.0038298 (2012).
31. Lei, Z. et al. MiR-142-3p represses TGF-beta-induced growth inhibition through repression of TGFbetaR1 in non-small cell lung cancer. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 28, 2696–2704, doi: 10.1096/fj.13-242788 (2014).
32. Isebe, T. et al. miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway: elife 3, doi: 10.7554/eLife.01977 (2014).
33. Wolschansky, Z. et al. Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clinica chimica acta; international journal of clinical chemistry 416, 5–10, doi: 10.1016/j.cca.2012.11.010 (2013).
34. Lian, J. H., Wang, W. H., Wang, J. Q., Zhang, Y. H. & Li, Y. MicroRNA-122 promotes proliferation, invasion and migration of renal cell carcinoma cells through the PI3K/Akt signaling pathway. *Asian Pacific journal of cancer prevention: APJCP* 14, 5017–5021 (2013).
35. Fong, M. Y. et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. *Nature cell biology* 17, 183–194, doi: 10.1038/ncb3094 (2015).
36. Ng, K. W. et al. Piwi-interacting RNAs in cancer: emerging functions and clinical utility. *Molecular cancer* 15, 5, doi: 10.1186/s12943-016-0491-9 (2016).
37. Martinez, V. D. et al. Unique somatic and malignant expression patterns implicate PIWI-interacting RNAs in cancer-type specific biology. *Scientific reports* 5, 10423, doi: 10.1038/srep10423 (2015).
38. Mahn, R. et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. *Urology* 77, 1265.e1269–1216, doi: 10.1016/j.urology.2011.01.020 (2011).
39. Scheffer, A. R. et al. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? *World journal of urology* 32, 353–358, doi: 10.1007/s00345-012-1010-2 (2014).
40. Brase, J. C., Wuttig, D., Kurer, R. & Sultmann, H. Serum microRNAs as non-invasive biomarkers for cancer. *Molecular cancer* 9, 306, doi: 10.1186/1476-4598-9-306 (2010).
41. Blondeau, J. J. et al. Identification of novel long non-coding RNAs in clear cell renal cell carcinoma. *Clinical epigenetics* 7, 10, doi: 10.1186/1476-4598-14-9 (2015).
42. Yates, A. et al. Ensembl 2016. *Nucleic acids research* 44, D710–D716, doi: 10.1093/nar/gkv1157 (2016).
43. Rosenbloom, K. et al. The UCSC Genome Browser database: 2015 update. *Nucleic acids research* 43, D670–D681, doi: 10.1093/nar/gku1177 (2015).
44. Kozomara, A. & Griffiths-Jones, S. miRBase: integrating microRNA annotation and deep-sequencing data. *Nucleic acids research* 39, D152–D157, doi: 10.1093/nar/gkq1027 (2011).
45. Chan, P. P. & Lowe, T. M. GtRNAdb: a database of transfer RNA genes detected in genomic sequence. *Nucleic acids research* 37, D93–D97, doi: 10.1093/nar/gkn787 (2009).
46. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* (Oxford, England) 26, 139–140, doi: 10.1093/bioinformatics/btp616 (2010).
47. Anders, S. et al. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. *Nat Protoc* 8, 1755–1786, doi: 10.1038/nprot.2013.099 (2013).
48. Robinson, M. D. & Smyth, G. K. Small-sample estimation of negative binomial dispersion, with applications to SAGE data. *Biostatistics* 9, 321–332, doi: 10.1093/biostatistics/kxm030 (2008).
49. Sanders, I. et al. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. *International journal of urology: official journal of the Japanese Urological Association* 19, 1017–1025, doi: 10.1111/j.1442-2042.2012.03082.x (2012).

Acknowledgements
The collection of tissue samples was performed within the framework of the Biobank of the Center for Integrated Oncology Köln Bonn.

Author Contributions
M.N. and D.S. performed the experiments. M.D. performed bioinformatic analyses. S.P. reviewed the pathological specimen. M.N. and J.E. wrote the manuscript. S.P. and S.C.M. helped to improve the scientific structure of the manuscript. All authors participated in results discussion. The final paper was reviewed by all co-authors.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Nientiedt, M. et al. Identification of aberrant tRNA-halves expression patterns in clear cell renal cell carcinoma. *Sci. Rep.* 6, 37158; doi: 10.1038/srep37158 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2016